Financials in USD. Standardized financial statements.
A compact view of how Intercept Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $285.71M | $363.47M | $312.69M | $252.00M | $179.80M | $130.96M | $24.95M | $2.78M | $1.74M | $1.62M |
| Revenue Growth? | -21.4% | +16.2% | +24.1% | +40.2% | +37.3% | +424.9% | +796.9% | +59.7% | +7.4% | 0.0% |
| Cost of Revenue? | $984,000 | $3.10M | $5.32M | $4.21M | $2.52M | $1.37M | $0 | $0 | $0 | $0 |
| Gross Profit? | $284.73M | $360.37M | $307.37M | $247.79M | $177.28M | $129.59M | $24.95M | $2.78M | $1.74M | $1.62M |
| Gross Margin? | +99.7% | +99.1% | +98.3% | +98.3% | +98.6% | +99.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $352.94M | $416.13M | $523.98M | $560.22M | $462.77M | $465.20M | $427.49M | $231.94M | $114.91M | $41.07M |
| Operating Income? | -$68.22M | -$55.76M | -$216.61M | -$312.43M | -$285.49M | -$335.61M | -$402.54M | -$229.16M | -$113.17M | -$39.45M |
| EBITDA? | -$61.70M | -$34.85M | -$212.20M | -$294.65M | -$278.72M | -$331.10M | -$398.63M | -$226.43M | $57.66M | -$10.90M |
| Income Before Tax | -$174.86M | -$91.43M | -$274.88M | -$344.68M | -$309.24M | -$360.37M | -$412.83M | -$226.43M | -$283.23M | -$67.79M |
| Income Tax Expense | -$290.03M | $53.60M | $49.35M | $46.37M | $0 | $0 | $0 | $1.04M | $0 | $0 |
| Net Income? | $115.17M | -$145.02M | -$324.23M | -$391.05M | -$309.24M | -$360.37M | -$412.83M | -$226.43M | -$283.23M | -$67.79M |
| EPS? | $3.41 | $-4.55 | $-9.83 | $-12.35 | $-10.86 | $-14.38 | $-16.74 | $-9.56 | $-13.63 | $-3.76 |
| Diluted EPS? | $3.40 | $-4.55 | $-9.83 | $-12.35 | $-10.86 | $-14.38 | $-16.74 | $-9.56 | $-13.63 | $-3.76 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality